MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-05-2026
Sotera Health Company Gross Profit 2011-2026 | SHC
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Sotera Health Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 646 M | 602 M | 577 M | 557 M | 519 M | 444 M | 395 M | 357 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 646 M | 357 M | 512 M |
Quarterly Gross Profit Sotera Health Company
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 147 M | 178 M | 167 M | 135 M | 158 M | 153 M | 127 M | 146 M | 140 M | 112 M | - | 136 M | 150 M | 129 M | - | 126 M | 144 M | 115 M | - | 108 M | 119 M | 96.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 178 M | 96.5 M | 136 M |
Gross Profit of other stocks in the Diagnostics research industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
7.85 M | - | -8.98 % | $ 14.8 K |  USA |
 |
Centogene N.V.
CNTG
|
17.2 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Heska Corporation
HSKA
|
111 M | - | - | $ 1.31 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
2.69 B | $ 206.18 | 0.82 % | $ 22.9 B | USA |
|
Akumin
AKU
|
53.5 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Co-Diagnostics
CODX
|
400 K | $ 4.63 | 2.88 % | $ 6.16 M | USA |
 |
Castle Biosciences
CSTL
|
53 M | $ 21.44 | 1.68 % | $ 621 M | USA |
 |
Fulgent Genetics
FLGT
|
131 M | $ 19.12 | 3.35 % | $ 588 M | USA |
 |
Aspira Women's Health
AWH
|
5.92 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
2.7 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
6.12 M | - | -13.05 % | $ 7.29 M | USA |
 |
ICON Public Limited Company
ICLR
|
817 M | $ 152.76 | 0.62 % | $ 12 B |  Irlanda |
 |
Oxford Immunotec Global PLC
OXFD
|
54.4 M | - | - | $ 562 M |  Britain |
 |
Guardant Health
GH
|
144 M | $ 131.71 | 1.22 % | $ 16.5 B | USA |
 |
Illumina
ILMN
|
2.87 B | $ 165.78 | 3.59 % | $ 25.7 B | USA |
 |
CareDx, Inc
CDNA
|
81.6 M | $ 23.21 | 2.02 % | $ 1.24 B | USA |
 |
Chembio Diagnostics
CEMI
|
6.58 M | - | 0.22 % | $ 16.8 M | USA |
 |
Interpace Biosciences
IDXG
|
24.1 M | $ 1.74 | 3.57 % | $ 7.7 M | USA |
 |
HTG Molecular Diagnostics
HTGM
|
4.56 M | - | -20.0 % | $ 1.06 M | USA |
 |
Global Cord Blood Corporation
CO
|
1.06 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
83.3 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-240 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
281 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
276 K | - | -11.32 % | $ 2.94 M | USA |
 |
Lantheus Holdings
LNTH
|
942 M | $ 102.44 | 2.46 % | $ 6.91 B | USA |
 |
Charles River Laboratories International
CRL
|
958 M | $ 193.18 | 1.68 % | $ 9.57 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
869 M | - | - | $ 10.7 B | USA |
 |
Pacific Biosciences of California
PACB
|
45.8 M | $ 1.42 | 3.28 % | $ 426 M | USA |
 |
Medpace Holdings
MEDP
|
246 M | $ 475.39 | 1.84 % | $ 13.7 B | USA |
 |
Exact Sciences Corporation
EXAS
|
2.26 B | - | - | $ 19.8 B | USA |
 |
Mettler-Toledo International
MTD
|
2.39 B | $ 1 162.13 | -0.07 % | $ 24 B |  Schweiz |
 |
NeoGenomics
NEO
|
314 M | $ 11.74 | 2.62 % | $ 1.5 B | USA |
 |
Myriad Genetics
MYGN
|
577 M | $ 4.66 | 2.53 % | $ 432 M | USA |
 |
National Research Corporation
NRC
|
81.5 M | $ 20.98 | 6.23 % | $ 470 M | USA |
 |
Natera
NTRA
|
127 M | $ 222.41 | -0.19 % | $ 30.4 B | USA |
 |
Personalis
PSNL
|
22.1 M | $ 10.26 | 5.23 % | $ 916 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
8.06 B | $ 25.84 | -2.49 % | $ 24.5 B |  Niderland |
 |
Senseonics Holdings
SENS
|
15.8 M | $ 7.65 | 2.9 % | $ 319 M | USA |
 |
QIAGEN N.V.
QGEN
|
1.3 B | - | - | $ 10.6 B | Niderland |
 |
Soleno Therapeutics
SLNO
|
-58.5 K | - | - | $ 2.69 B | USA |
 |
Biomerica
BMRA
|
498 K | $ 2.03 | -1.02 % | $ 4.66 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
4.01 B | $ 274.38 | 1.17 % | $ 22.8 B | USA |
 |
Thermo Fisher Scientific
TMO
|
11.3 B | $ 492.63 | -0.34 % | $ 186 B | USA |
 |
Trinity Biotech plc
TRIB
|
21.4 M | $ 0.68 | 2.39 % | $ 244 M | Irlanda |
 |
Motus GI Holdings
MOTS
|
-398 K | - | -34.28 % | $ 263 K |  Israel |
 |
Twist Bioscience Corporation
TWST
|
6.96 M | $ 70.12 | 0.09 % | $ 4.19 B | USA |
 |
Neogen Corporation
NEOG
|
421 M | $ 9.32 | 0.38 % | $ 2.02 B | USA |
 |
Invitae Corporation
NVTA
|
98.7 M | - | - | $ 21.2 M | USA |